Literature DB >> 12573034

High-mobility group A1 proteins are overexpressed in human leukaemias.

Giovanna Maria Pierantoni1, Valter Agosti, Monica Fedele, Heather Bond, Irene Caliendo, Gennaro Chiappetta, Francesco Lo Coco, Fabrizio Pane, Maria Caterina Turco, Giovanni Morrone, Salvatore Venuta, Alfredo Fusco.   

Abstract

High-mobility group A (HMGA) proteins are non-histone nuclear proteins that bind DNA and several transcription factors. They are involved in the regulation of chromatin structure and function. HMGA protein expression is low in normal adult tissues, but abundant during embryonic development and in several human tumours. Rearrangements of the HMGA genes have been frequently detected in human benign tumours of mesenchymal origin, e.g. lipomas, lung hamartomas and uterine leiomiomas. HMGA proteins have been implicated in the control of cell growth and differentiation of the pre-adipocytic cell line 3T3-L1. In an attempt to better understand the role of HMGA1 proteins in haematological neoplasias and in the differentiation of haematopietic cells, we have investigated their expression in human leukaemias and in leukaemic cell lines induced to terminal differentiation. Here we report HMGA1 overexpression in most fresh human leukaemias of different origin and in several leukaemic cell lines. Moreover, differentiation of three cell lines towards the megakaryocytic phenotype was associated with HMGA1 protein induction, whereas induction of erythroid and monocytic differentiation generally resulted in reduced HMGA1 expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573034      PMCID: PMC1223365          DOI: 10.1042/BJ20021493

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia.

Authors:  B Santulli; B Kazmierczak; R Napolitano; I Caliendo; G Chiappetta; V Rippe; J Bullerdiek; A Fusco
Journal:  Cancer Genet Cytogenet       Date:  2000-05

Review 2.  Hematopoietic development: a balancing act.

Authors:  A B Cantor; S H Orkin
Journal:  Curr Opin Genet Dev       Date:  2001-10       Impact factor: 5.578

3.  Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors.

Authors:  M F Romano; A Lamberti; R Bisogni; C Garbi; A M Pagnano; P Auletta; P Tassone; M C Turco; S Venuta
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

4.  Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix.

Authors:  A Bandiera; D Bonifacio; G Manfioletti; F Mantovani; A Rustighi; F Zanconati; A Fusco; L Di Bonito; V Giancotti
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

5.  JURL-MK1 (c-kit(high)/CD30-/CD40-) and JURL-MK2 (c-kit(low)/CD30+/CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis.

Authors:  R Di Noto; L Luciano; C Lo Pardo; F Ferrara; F Frigeri; O Mercuro; M L Lombardi; F Pane; C Vacca; C Manzo; F Salvatore; B Rotoli; L Del Vecchio
Journal:  Leukemia       Date:  1997-09       Impact factor: 11.528

6.  Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation.

Authors:  R M Melillo; G M Pierantoni; S Scala; S Battista; M Fedele; A Stella; M C De Biasio; G Chiappetta; V Fidanza; G Condorelli; M Santoro; C M Croce; G Viglietto; A Fusco
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

7.  High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases.

Authors:  G Chiappetta; G Manfioletti; F Pentimalli; N Abe; M Di Bonito; M T Vento; A Giuliano; M Fedele; G Viglietto; M Santoro; T Watanabe; V Giancotti; A Fusco
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

8.  HMG-I/Y, a new c-Myc target gene and potential oncogene.

Authors:  L J Wood; M Mukherjee; C E Dolde; Y Xu; J F Maher; T E Bunton; J B Williams; L M Resar
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

9.  Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway.

Authors:  G Baldassarre; M Fedele; S Battista; A Vecchione; A J Klein-Szanto; M Santoro; T A Waldmann; N Azimi; C M Croce; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

10.  Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins.

Authors:  N Abe; T Watanabe; T Masaki; T Mori; M Sugiyama; H Uchimura; Y Fujioka; G Chiappetta; A Fusco; Y Atomi
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

View more
  20 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

Review 2.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

3.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

Review 4.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

5.  High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells.

Authors:  Yang Xi; Yu-Sang Li; He-Bin Tang
Journal:  Mol Cell Biochem       Date:  2012-11-16       Impact factor: 3.396

6.  The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer.

Authors:  Bethany M Bush; Ashton T Brock; Jiayue A Deng; Ronald A Nelson; Takita Felder Sumter
Journal:  Cell Biochem Funct       Date:  2012-09-07       Impact factor: 3.685

Review 7.  Critical role of the high mobility group A proteins in hematological malignancies.

Authors:  Marco De Martino; Francesco Esposito; Alfredo Fusco
Journal:  Hematol Oncol       Date:  2021-10-12       Impact factor: 4.850

8.  New insight into CCN3 interactions--nuclear CCN3 : fact or fantasy?

Authors:  Bernard Perbal
Journal:  Cell Commun Signal       Date:  2006-08-08       Impact factor: 5.712

9.  Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast.

Authors:  Piotr Ziółkowski; Elzbieta Gamian; Beata Osiecka; Alexandre Zougman; Jacek R Wiśniewski
Journal:  J Biomed Biotechnol       Date:  2009-12-24

10.  Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation.

Authors:  Andrew Pierce; Andrew Williamson; Ewa Jaworska; John R Griffiths; Sam Taylor; Michael Walker; Mark Aspinall-O'Dea; Mark Aspinall O'Dea; Elaine Spooncer; Richard D Unwin; Toryn Poolman; David Ray; Anthony D Whetton
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.